Optimal sequence-based design for multi-antigen HIV-1 vaccines using minimally distant antigens

The immense global diversity of HIV-1 is a significant obstacle to developing a safe and effective vaccine. We recently showed that infections established with multiple founder variants are associated with the development of neutralization breadth years later. We propose a novel vaccine design strategy that integrates the variability observed in acute HIV-1 infections with multiple founder variants. We developed a probabilistic model to simulate this variability, yielding a set of sequences that present the minimal diversity seen in an infection with multiple founders. We applied this model to a subtype C consensus sequence for the Envelope (Env) (used as input) and showed that the simulated Env sequences mimic the mutational landscape of an infection with multiple founder variants, including diversity at antibody epitopes. The derived set of multi-founder-variant-like, minimally distant antigens is designed to be used as a vaccine cocktail specific to a HIV-1 subtype or circulating recombinant form and is expected to promote the development of broadly neutralizing antibodies.

[1]  S. Ovchinnikov,et al.  ColabFold: making protein folding accessible to all , 2022, Nature Methods.

[2]  Bethany L. Dearlove,et al.  HIV-1 infections with multiple founders associate with the development of neutralization breadth , 2022, PLoS pathogens.

[3]  Oriol Vinyals,et al.  Highly accurate protein structure prediction with AlphaFold , 2021, Nature.

[4]  E. Giorgi,et al.  Different evolutionary pathways of HIV-1 between fetus and mother perinatal transmission pairs indicate unique immune selection in fetuses , 2021, Cell reports. Medicine.

[5]  Jerome H. Kim,et al.  RV144 vaccine imprinting constrained HIV-1 evolution following breakthrough infection , 2021, Virus evolution.

[6]  M. Andrasik,et al.  Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120/MF59 in Adults , 2021, The New England journal of medicine.

[7]  Allan C. deCamp,et al.  Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. , 2021, The New England journal of medicine.

[8]  J. Mascola,et al.  B cell engagement with HIV-1 founder virus envelope predicts development of broadly neutralizing antibodies. , 2021, Cell host & microbe.

[9]  Lydia Bonar,et al.  Factors influencing estimates of HIV-1 infection timing using BEAST , 2021, PLoS Comput. Biol..

[10]  Jerome H. Kim,et al.  RV144 HIV-1 vaccination impacts post-infection antibody responses , 2020, PLoS pathogens.

[11]  Bethany L. Dearlove,et al.  A SARS-CoV-2 vaccine candidate would likely match all currently circulating variants , 2020, Proceedings of the National Academy of Sciences.

[12]  M. Feinberg,et al.  Tetravalent Immunogen Assembled from Conserved Regions of HIV-1 and Delivered as mRNA Demonstrates Potent Preclinical T-Cell Immunogenicity and Breadth , 2020, Vaccines.

[13]  J. P. Labuschagne,et al.  Molecular dating and viral load growth rates suggested that the eclipse phase lasted about a week in HIV-1 infected adults in East Africa and Thailand , 2020, PLoS pathogens.

[14]  Olga Chernomor,et al.  IQ-TREE 2: New Models and Efficient Methods for Phylogenetic Inference in the Genomic Era , 2019, bioRxiv.

[15]  S. Kabra,et al.  Broadly neutralizing plasma antibodies effective against autologous circulating viruses in infants with multivariant HIV-1 infection , 2019, Nature Communications.

[16]  E. Lewitus,et al.  A non-parametric analytic framework for within-host viral phylogenies and a test for HIV-1 founder multiplicity , 2019, Virus evolution.

[17]  Ruchi M. Newman,et al.  Structural topology defines protective CD8+ T cell epitopes in the HIV proteome , 2019, Science.

[18]  M. Rolland.  HIV-1 phylogenetics and vaccines , 2019, Current opinion in HIV and AIDS.

[19]  L. Morris,et al.  HIV Superinfection Drives De Novo Antibody Responses and Not Neutralization Breadth , 2018, Cell host & microbe.

[20]  M Mirdita,et al.  MMseqs2 desktop and local web server app for fast, interactive sequence searches , 2018, bioRxiv.

[21]  The Swiss Hiv Cohort Study,et al.  Tracing HIV-1 strains that imprint broadly neutralizing antibody responses , 2018, Nature.

[22]  Galit Alter,et al.  Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19) , 2018, The Lancet.

[23]  Bjoern Peters,et al.  BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes , 2017, Nucleic Acids Res..

[24]  Thomas K. F. Wong,et al.  ModelFinder: Fast Model Selection for Accurate Phylogenetic Estimates , 2017, Nature Methods.

[25]  A. Trkola,et al.  Determinants of HIV-1 broadly neutralizing antibody induction , 2016, Nature Medicine.

[26]  Cinque S. Soto,et al.  Developmental Pathway of the MPER-Directed HIV-1-Neutralizing Antibody 10E8 , 2016, PloS one.

[27]  Jerome H. Kim,et al.  Prospective Study of Acute HIV-1 Infection in Adults in East Africa and Thailand. , 2016, The New England journal of medicine.

[28]  Sergei L. Kosakovsky Pond,et al.  Differences in the Selection Bottleneck between Modes of Sexual Transmission Influence the Genetic Composition of the HIV-1 Founder Virus , 2016, PLoS pathogens.

[29]  A. Mchardy,et al.  Determination of antigenicity-altering patches on the major surface protein of human influenza A/H3N2 viruses , 2016, Virus evolution.

[30]  Ben Murrell,et al.  Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort , 2016, PLoS pathogens.

[31]  Lynn Morris,et al.  New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency , 2015, Journal of Virology.

[32]  Trevor Bedford,et al.  Prediction, dynamics, and visualization of antigenic phenotypes of seasonal influenza viruses , 2015, Proceedings of the National Academy of Sciences.

[33]  Eric Lewitus,et al.  Characterizing and comparing phylogenies from their Laplacian spectrum , 2015, bioRxiv.

[34]  R. Sanjuán,et al.  Extremely High Mutation Rate of HIV-1 In Vivo , 2015, PLoS biology.

[35]  Alan S. Perelson,et al.  Competitive exclusion by autologous antibodies can prevent broad HIV-1 antibodies from arising , 2015, Proceedings of the National Academy of Sciences.

[36]  Jerome H. Kim,et al.  HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders , 2015, Nature Medicine.

[37]  Xiping Shen,et al.  Computational Identification of Antigenicity-Associated Sites in the Hemagglutinin Protein of A/H1N1 Seasonal Influenza Virus , 2015, PloS one.

[38]  N. Haigwood,et al.  Emergence of Broadly Neutralizing Antibodies and Viral Coevolution in Two Subjects during the Early Stages of Infection with Human Immunodeficiency Virus Type 1 , 2014, Journal of Virology.

[39]  Feng Gao,et al.  Cooperation of B Cell Lineages in Induction of HIV-1-Broadly Neutralizing Antibodies , 2014, Cell.

[40]  Gwo-Yu Chuang,et al.  Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-120 interface , 2014, Nature.

[41]  Jerome H. Kim,et al.  Polyfunctional Fc-Effector Profiles Mediated by IgG Subclass Selection Distinguish RV144 and VAX003 Vaccines , 2014, Science Translational Medicine.

[42]  M. Lässig,et al.  A predictive fitness model for influenza , 2014, Nature.

[43]  B. Korber,et al.  Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection , 2014, AIDS.

[44]  Holly Janes,et al.  Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. , 2013, The New England journal of medicine.

[45]  L. Morris,et al.  Viral Escape from HIV-1 Neutralizing Antibodies Drives Increased Plasma Neutralization Breadth through Sequential Recognition of Multiple Epitopes and Immunotypes , 2013, PLoS pathogens.

[46]  Ryan McBride,et al.  Broadly Neutralizing Antibody PGT121 Allosterically Modulates CD4 Binding via Recognition of the HIV-1 gp120 V3 Base and Multiple Surrounding Glycans , 2013, PLoS pathogens.

[47]  Tongqing Zhou,et al.  Somatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 Neutralization , 2013, Cell.

[48]  K. Katoh,et al.  MAFFT Multiple Sequence Alignment Software Version 7: Improvements in Performance and Usability , 2013, Molecular biology and evolution.

[49]  M. Davenport,et al.  The origin of genetic diversity in HIV-1. , 2012, Virus research.

[50]  Lynn Morris,et al.  Evolution of an HIV glycan–dependent broadly neutralizing antibody epitope through immune escape , 2012, Nature Medicine.

[51]  Tomer Hertz,et al.  Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env-V2 , 2012, Nature.

[52]  David Nemazee,et al.  Rational immunogen design to target specific germline B cell receptors , 2012, Retrovirology.

[53]  Alice Carolyn McHardy,et al.  Inference of Genotype–Phenotype Relationships in the Antigenic Evolution of Human Influenza A (H3N2) Viruses , 2012, PLoS Comput. Biol..

[54]  A. Trkola,et al.  HIV-1 Superinfection in Women Broadens and Strengthens the Neutralizing Antibody Response , 2012, PLoS pathogens.

[55]  J. Kublin,et al.  Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. , 2011, The Lancet. Infectious diseases.

[56]  L. Morris,et al.  The Neutralization Breadth of HIV-1 Develops Incrementally over Four Years and Is Associated with CD4+ T Cell Decline and High Viral Load during Acute Infection , 2011, Journal of Virology.

[57]  M. Altfeld,et al.  Characteristics of the Earliest Cross-Neutralizing Antibody Response to HIV-1 , 2011, PLoS pathogens.

[58]  Mario Roederer,et al.  Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1 , 2010, Science.

[59]  R. Powell,et al.  Infection by Discordant Strains of HIV-1 Markedly Enhances the Neutralizing Antibody Response against Heterologous Virus , 2010, Journal of Virology.

[60]  Bette Korber,et al.  Mosaic HIV-1 Vaccines Expand the Breadth and Depth of Cellular Immune Responses in Rhesus Monkeys , 2010, Nature Medicine.

[61]  M. Robb,et al.  Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. , 2009, The New England journal of medicine.

[62]  J. Baeten,et al.  Breadth of Neutralizing Antibody Response to Human Immunodeficiency Virus Type 1 Is Affected by Factors Early in Infection but Does Not Influence Disease Progression , 2009, Journal of Virology.

[63]  Terri Wrin,et al.  Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm , 2009, Journal of Virology.

[64]  R. Swanstrom,et al.  Quantitating the Multiplicity of Infection with Human Immunodeficiency Virus Type 1 Subtype C Reveals a Non-Poisson Distribution of Transmitted Variants , 2009, Journal of Virology.

[65]  Devan V Mehrotra,et al.  Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial , 2008, The Lancet.

[66]  Xuesong Yu,et al.  Factors Associated with the Development of Cross-Reactive Neutralizing Antibodies during Human Immunodeficiency Virus Type 1 Infection , 2008, Journal of Virology.

[67]  Vicki C. Ashley,et al.  Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia , 2008, Journal of Virology.

[68]  O. Gascuel,et al.  An improved general amino acid replacement matrix. , 2008, Molecular biology and evolution.

[69]  Hui Li,et al.  Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection , 2008, Proceedings of the National Academy of Sciences.

[70]  James I Mullins,et al.  HIV-1 Group M Conserved Elements Vaccine , 2007, PLoS pathogens.

[71]  Bette Korber,et al.  Design and Pre-Clinical Evaluation of a Universal HIV-1 Vaccine , 2007, PloS one.

[72]  D. Nickle,et al.  Reconstruction and Function of Ancestral Center-of-Tree Human Immunodeficiency Virus Type 1 Proteins , 2007, Journal of Virology.

[73]  Punnee Pitisuttithum,et al.  Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. , 2006, The Journal of infectious diseases.

[74]  Kenneth H Mayer,et al.  Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. , 2005, The Journal of infectious diseases.

[75]  Martin A. Nowak,et al.  Antibody neutralization and escape by HIV-1 , 2003, Nature.

[76]  D. Richman,et al.  Rapid evolution of the neutralizing antibody response to HIV type 1 infection , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[77]  Feng Gao,et al.  Diversity Considerations in HIV-1 Vaccine Selection , 2002, Science.

[78]  B. Korber,et al.  Evolutionary and immunological implications of contemporary HIV-1 variation. , 2001, British medical bulletin.

[79]  Bette T. Korber,et al.  Detecting hypermutations in viral sequences with an emphasis on G A hypermutation , 2000, Bioinform..

[80]  K Bebenek,et al.  The accuracy of reverse transcriptase from HIV-1. , 1988, Science.

[81]  James Theiler,et al.  Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants , 2007, Nature Medicine.

[82]  BIOINFORMATICS APPLICATIONS NOTE Structural bioinformatics , 2005 .